Table 2.
Type of infections, duration of treatment and clinical efficacy of tigecycline
| Type of infections | n (%) |
Duration of treatment, days Median (range) |
Clinical efficacy n (%) |
Clinical failure n (%) |
|---|---|---|---|---|
| Secondary peritonitis | 46 (22) | 9 (6- 18) | 40 (88) | 6 (12) |
| Tertiary peritonitis | 41 (20) | 15 ( 11-28) | 32(78) | 9 (22) |
| Other abdominal infections | 12(6) | 11 (7-17) | 5 (42) | 7 (58) |
| Pneumonia ( HAP, HCAP, VAP) | 27 (13) | 12 ( 8-21) | 18 (67) | 9 (33) |
| Pneumonia and bloodstream infections | 29 (14) | 17 (13-24) | 19 (66) | 10 (34) |
| Bloodstream infections | 23 (11) | 15 (12-18) | 16 (70) | 7 (30) |
| Complicated skin and soft tissue infections | 17 (8) | 11 (7-18) | 13(76) | 4 (24) |
| Empiric use in neutropenic | 12 (6) | 14 (9-17) | 7 (58) | 5(42) |
| Total | 207 (100) | 151 (73) | 56 (27) |
HAP: hospital acquired pneumonia, HCAP: health care associated pneumonia, VAP: ventilator associated pneumonia